Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | CYAD-211 |
| Trade Name | |
| Synonyms | CYAD211|CYAD 211 |
| Drug Descriptions |
CYAD-211 is a B cell maturation antigen (BCMA)-targeting chimeric antigen receptor T cell (CAR-T) therapy that coexpresses an shRNA targeting CD3z, which potentially induces killing of BCMA-expressing tumor cells (Blood 2021 138:2817, NCI Drug Dictionary). |
| DrugClasses | TNFRSF17 Immune Cell Therapy 27 |
| CAS Registry Number | NA |
| NCIT ID | C176885 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| CYAD-211 | CYAD-211 | 0 | 1 |